This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Smith, T. J. Articles by Pool, G. E. Search for Related Content PubMed PubMed Citation Articles by Smith, T. J. Articles by Pool, G. E. Social Bookmarking                            What's this?

Randomized Clinical Trial of an Implantable Drug Delivery System Compared With Comprehensive Medical Management for Refractory Cancer Pain: Impact on Pain, Drug-Related Toxicity, and Survival

From the Medical College of Virginia Campus of Virginia Commonwealth University, Richmond, VA; Johns Hopkins University Medical Center, Baltimore, MD; Center for Pain Relief, Charleston, WV; Valley Pain Treatment Center, Scottsdale, AZ; The Center for Clinical Research, Winston-Salem, NC; University of Minnesota, Minneapolis, MN; Marshfield Clinic, Marshfield, WI; Hospital de Zone, Morges, Switzerland; and Hospital de la Santa Creu I Sant Pau, Barcelona, Spain.

Address reprint requests to Thomas J. Smith, MD, Division of Hematology/Oncology, Virginia Commonwealth University, MCV Box 980230, Richmond, VA 23298-0230; email: tsmith{at}hsc.vcu.edu

PURPOSE: Implantable intrathecal drug delivery systems (IDDSs) have been used to manage refractory cancer pain, but there are no randomized clinical trial (RCT) data comparing them with comprehensive medical management (CMM).

PATIENTS AND METHODS: We enrolled 202 patients on an RCT of CMM versus IDDS plus CMM. Entry criteria included unrelieved pain (visual analog scale [VAS] pain scores 5 on a 0 to 10 scale). Clinical success was defined as 20% reduction in VAS scores, or equal scores with 20% reduction in toxicity. The main outcome measure was pain control combined with change of toxicity, as measured by the National Cancer Institute Common Toxicity Criteria, 4 weeks after randomization.

RESULTS: Sixty of 71 IDDS patients (84.5%) achieved clinical success compared with 51 of 72 CMM patients (70.8%, P = .05). IDDS patients more often achieved 20% reduction in both pain VAS and toxicity (57.7% [41 of 71] v 37.5% [27 of 72], P = .02). The mean CMM VAS score fell from 7.81 to 4.76 (39% reduction); for the IDDS group, the scores fell from 7.57 to 3.67 (52% reduction, P = .055). The mean CMM toxicity scores fell from 6.36 to 5.27 (17% reduction); for the IDDS group, the toxicity scores fell from 7.22 to 3.59 (50% reduction, P = .004). The IDDS group had significant reductions in fatigue and depressed level of consciousness (P < .05). IDDS patients had improved survival, with 53.9% alive at 6 months compared with 37.2% of the CMM group (P = .06).

CONCLUSION: IDDSs improved clinical success in pain control, reduced pain, significantly relieved common drug toxicities, and improved survival in patients with refractory cancer pain.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				P. G. Fine and S. Brogan Interventional Approaches to Treating Cancer Pain ASCO Educational Book, January 1, 2009; 2009(1): 583 - 588. [Abstract] [Full Text] [PDF]

				W. A. Chambers Nerve blocks in palliative care Br. J. Anaesth., July 1, 2008; 101(1): 95 - 100. [Abstract] [Full Text] [PDF]

				S. E. Harrington and T. J. Smith The Role of Chemotherapy at the End of Life: "When Is Enough, Enough?" JAMA, June 11, 2008; 299(22): 2667 - 2678. [Abstract] [Full Text] [PDF]

				Sensory neuron targeting by self-complementary AAV8 via lumbar puncture for chronic pain PNAS, January 22, 2008; 105(3): 1055 - 1060.

				K. A. Lorenz, J. Lynn, S. M. Dy, L. R. Shugarman, A. Wilkinson, R. A. Mularski, S. C. Morton, R. G. Hughes, L. K. Hilton, M. Maglione, et al. Evidence for Improving Palliative Care at the End of Life: A Systematic Review Ann Intern Med, January 15, 2008; 148(2): 147 - 159. [Abstract] [Full Text] [PDF]

				V. L. Ghafoor, M. Epshteyn, G. H. Carlson, D. M. Terhaar, O. Charry, and P. K. Phelps Intrathecal drug therapy for long-term pain management Am. J. Health Syst. Pharm., December 1, 2007; 64(23): 2447 - 2461. [Abstract] [Full Text] [PDF]

				E. A. Hahn, D. Cella, O. Chassany, D. L. Fairclough, G. Y. Wong, R. D. Hays, and Clinical Significance Consensus Meeting Group Precision of Health-Related Quality-of-Life Data Compared With Other Clinical Measures Mayo Clin. Proc., October 1, 2007; 82(10): 1244 - 1254. [Abstract] [Full Text] [PDF]

				J. C. Thompson, J. Wood, and D. Feuer Prostate cancer: palliative care and pain relief Br. Med. Bull., September 1, 2007; 83(1): 341 - 354. [Abstract] [Full Text] [PDF]

				J. P. Griffin, K. A. Koch, J. E. Nelson, and M. E. Cooley Palliative Care Consultation, Quality-of-Life Measurements, and Bereavement for End-of-Life Care in Patients With Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 404S - 422S. [Abstract] [Full Text] [PDF]

				T. J. Smith, P. J. Coyne, P. S. Staats, T. Deer, L. J. Stearns, R. L. Rauck, R. L. Boortz-Marx, E. Buchser, E. Catala, D. A. Bryce, et al. An implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (CMM) Ann. Onc., May 1, 2005; 16(5): 825 - 833. [Abstract] [Full Text] [PDF]

				J.M. Saroyan, W.S. Schechter, M.E. Tresgallo, and L. Granowetter Role of Intraspinal Analgesia in Terminal Pediatric Malignancy J. Clin. Oncol., February 20, 2005; 23(6): 1318 - 1321. [Full Text] [PDF]

				D. B. Carr, L. C. Goudas, E. M. Balk, R. Bloch, J. P. A. Ioannidis, and J. Lau Evidence Report on the Treatment of Pain in Cancer Patients J Natl Cancer Inst Monographs, July 1, 2004; 2004(32): 23 - 31. [Abstract] [Full Text] [PDF]

				J. M. Rosenow Management of Cancer Pain JAMA, March 3, 2004; 291(9): 1068 - 1068. [Full Text] [PDF]

				A. W. Burton, A. Rajagopal, C. S. Cleeland, S. J. Hassenbusch III, and D. B. Carr Management of Cancer Pain JAMA, March 3, 2004; 291(9): 1067 - 1068. [Full Text] [PDF]

				E. Bruera Management of Cancer Pain--Reply JAMA, March 3, 2004; 291(9): 1068 - 1069. [Full Text] [PDF]

				E. Bruera and H. N. Kim Cancer Pain JAMA, November 12, 2003; 290(18): 2476 - 2479. [Full Text] [PDF]

				M. P. Davis, D. Walsh, R. Lagman, and S. B. LeGrand Randomized Clinical Trial of an Implantable Drug Delivery System J. Clin. Oncol., July 15, 2003; 21(14): 2800 - 2801. [Full Text] [PDF]

				C. Ripamonti and C. Brunelli Randomized Clinical Trial of an Implantable Drug Delivery System Compared With Comprehensive Medical Management for Refractory Cancer Pain: Impact on Pain, Drug-Related Toxicity, and Survival J. Clin. Oncol., July 15, 2003; 21(14): 2801 - 2802. [Full Text] [PDF]

				T. J. Smith, P. Staats, and P. J. Coyne In reply: J. Clin. Oncol., July 15, 2003; 21(14): 2802 - 2803. [Full Text] [PDF]